



LIVER DISEASES: BACTERIAL AND AMOEBIC ABSCESES AND JAUNDICE IN LIVER CIRRHOSIS

*Nizomiddin Baratov,
Jamshidjon Urinboyev,
Mirziyod O'tkirov,
Gayrat Kurbanov,
Nodira Toshnazarova,
Yusup Utegenov.*

Abstract: *Liver diseases represent a major global health concern, encompassing infectious, inflammatory, and chronic degenerative conditions. Among these, bacterial and amoebic liver abscesses are significant causes of hepatic suppuration, while cirrhosis remains a final common pathway of chronic liver injury, frequently accompanied by jaundice. This article provides a comprehensive review of the etiology, pathogenesis, clinical manifestations, diagnostic approaches, and management strategies of bacterial and amoebic liver abscesses, as well as the mechanisms and clinical significance of jaundice in liver cirrhosis. Differential diagnostic considerations and a comparative analysis of disease presentations are also discussed.*

Introduction

The liver plays a central role in metabolism, detoxification, immune response, and bile formation. Diseases affecting the liver may compromise these functions, resulting in systemic manifestations. Liver abscesses are focal intrahepatic collections of pus caused by microbial infection, most commonly of bacterial or protozoal origin. Cirrhosis, on the other hand, is a chronic progressive disease characterized by fibrosis and nodular regeneration, ultimately leading to hepatic failure and portal hypertension. Jaundice, or icterus, characterized by hyperbilirubinemia and yellow discoloration of tissues, frequently accompanies these pathological conditions and provides important clinical clues.



Bacterial Liver Abscess

Etiology

Bacterial liver abscess (pyogenic liver abscess) arises from pyogenic organisms, most frequently *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Enterococcus* species, and anaerobes. The infection usually spreads via the portal vein from intra-abdominal infections, by biliary obstruction, direct extension, or hematogenous dissemination.

Pathogenesis. Pyogenic organisms induce localized hepatic necrosis through toxin-mediated and inflammatory mechanisms. Bile duct obstruction or portal bacteremia facilitates bacterial colonization, leading to abscess formation. Impaired immune response, diabetes mellitus, malignancies, and hepatobiliary instrumentation increase susceptibility.

Clinical Features

Patients commonly present with fever, chills, malaise, right upper quadrant pain, hepatomegaly, and leukocytosis. Jaundice may be present but is not universal; when present, it suggests biliary involvement or extensive parenchymal damage.

Diagnosis

Laboratory tests: elevated liver enzymes, leukocytosis, increased ESR/CRP.

Imaging: Ultrasound reveals hypoechoic or complex lesions; CT scanning is more sensitive.

Aspiration: confirms diagnosis and identifies causative organism.

Treatment. Management includes broad-spectrum antibiotics, percutaneous drainage, and treatment of underlying biliary pathology.

Amoebic Liver Abscess

Etiology

Amoebic liver abscess results from infection with *Entamoeba histolytica*, a protozoan parasite transmitted via fecal-oral contamination. The parasite invades colonic mucosa, enters the portal system, and reaches the liver.



Pathogenesis

Trophozoites induce hepatocellular necrosis and form characteristic “anchovy paste” abscesses. Unlike bacterial abscesses, these are often solitary and located in the right hepatic lobe.

Clinical Features

Common symptoms include fever, right upper abdominal pain, hepatomegaly, and weight loss. Jaundice is less common than in bacterial abscesses, occurring mainly when the lesion compresses bile ducts.

Diagnosis

Serology is highly sensitive and specific.

Ultrasound or CT reveals hypodense, rounded lesions.

Aspiration is reserved for atypical or refractory cases.

Treatment

Metronidazole is the primary therapy, followed by luminal agents to eradicate intestinal colonization.

Table 1. Comparative Features of Bacterial and Amoebic Liver Abscesses

Feature	Bacterial Liver Abscess	Amoebic Liver Abscess
Causative agent	Pyogenic bacteria	<i>Entamoeba histolytica</i>
Number of lesions	Often multiple	Usually solitary
Pain severity	Severe, acute	Moderate, subacute
Jaundice occurrence	Common	Less common
Diagnostic confirmation	Culture from aspiration	Serology and imaging
Primary treatment	Antibiotics + drainage	Metronidazole

Liver Cirrhosis and Jaundice

Pathogenesis of Cirrhosis

Cirrhosis results from chronic hepatocellular injury caused by viral hepatitis, alcoholism, metabolic disorders, and autoimmune disease. Progressive fibrosis disrupts lobular architecture, impairs blood flow, and diminishes hepatocellular function.



Mechanisms of Jaundice in Cirrhosis

Jaundice in cirrhosis is mainly due to:

Reduced hepatocellular uptake of bilirubin.

Impaired conjugation due to loss of functioning hepatocytes.

Reduced excretion due to cholestasis and bile canaliculi obstruction.

Clinical Features

Patients exhibit fatigue, pruritus, jaundice, ascites, spider angiomas, splenomegaly, and encephalopathy.

Diagnosis

Laboratory tests: elevated unconjugated and conjugated bilirubin, prolonged PT, decreased albumin.

Imaging: ultrasound showing coarse echotexture, nodularity.

Elastography assesses fibrosis severity.

Table 2. Jaundice in Cirrhosis vs Obstructive Jaundice

Feature	Cirrhotic Jaundice	Obstructive Jaundice
Bilirubin type	Mixed (conjugated + unconjugated)	Mainly conjugated
Stool color	Normal or dark	Clay-colored
Pruritus	Mild to moderate	Severe
Liver size	May be small, shrunken	Enlarged or normal

Conclusion

Bacterial and amoebic liver abscesses are significant infectious conditions requiring prompt diagnosis and management. Cirrhosis represents a chronic stage of liver injury often complicated by jaundice, reflecting severe impairment of hepatic function. Understanding the pathogenetic mechanisms, clinical characteristics, and differential diagnostic features of these conditions is essential for effective medical intervention and improved patient outcomes.

REFERENCES:

1. Тошназаров, Ш. М., Низомов, Б. У., Холлиев, Р. Х., & Тошназарова, Н. Ш. (2019). Эффективность применения бета-блокаторов при лечении дилатационной кардиомиопатии, осложненной хронической сердечной



недостаточностью II б стадии (по NYHA III ФК). *International scientific review*, (LXV), 107-108.

2. Агабабян, И. Р., Тошназарова, Н. Ш., Тошназаров, Ш. М., & Журакулов, Ф. Н. (2020). Рациональная гипотензивная терапия в профилактике хронической сердечной недостаточности у больных гипертонической болезнью. *Вестник науки и образования*, (24-3 (102)), 63-67.

3. Nodira, T. (2025). SYSTEMIC LUPUS ERYTHEMATOSUS AND CARDIOVASCULAR PATHOLOGY. *Eurasian Journal of Medical and Natural Sciences*, 5(3), 33-37.

4. Агабабян, И. Р., Ярашева, З. Х., & Тошназарова, Н. Ш. (2022). Тошназаров Ш. М. 4. *Достижения науки и образования*, 88.

5. Агабабян, И. Р., Ярашева, З. Х., Тошназарова, Н. Ш., & Тошназаров, Ш. М. (2022). ОЦЕНКА ЭФФЕКТИВНОСТИ КОМБИНИРОВАННОГО ПРИМЕНЕНИЯ АНТАГОНИСТОВ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II И СЕРДЕЧНЫХ ГЛИКОЗИДОВ ПРИ ЛЕЧЕНИИ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ, ОСЛОЖНЕННОЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ II Б СТАДИИ (ПО NYHA III ФК). *Достижения науки и образования*, (1 (81)), 88-90.

6. Buvamukhamedova, N. T., Jabbarov, O. O., Mirzayeva, G. F., & Madazimova, D. K. (2021). PROSPECTS OF RIVAROXABAN USE IN THE TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE. *Oriental renaissance: Innovative, educational, natural and social sciences*, 1(11), 496-502.

7. Эшонкулов, Ж. Х., Жаббаров, О. О., Умарова, З. Ф., Мадазимова, Д. Х., & Жуманазаров, С. Б. (2022). COVID-19 Инфекцияси ўтказган беморларда буйракларнинг зарарланиш патогенези.

8. Мадазимова, Д., & Жаббаров, А. (2022). COVID 19 ЎТКАЗГАН СУРУНКАЛИ БУЙРАК КАСАЛЛИГИ БОР БЕМОЛЛАРДА БУЙРАКЛАРНИНГ ФУНКЦИОНАЛ ҲОЛАТИНИ БАҲОЛАШ.



9. Умарова, З. Ф., Жаббаров, О. О., & Мадазимова, Д. Х. (2021). Изменение Функционального Состояния Почек У Больных Хронической Болезнью Почек Iii Стадии В Результате Применения Проренала. *Central Asian Journal of Medical and Natural Science*, 2(6), 343-348.
10. Madazimova, D., Jabborov, O., Nazarova, N., & Farmonov, A. (2021). EVALUATION OF RENAL AND CENTRAL HEMODYNAMICS IN PATIENTS WITH CHRONIC KIDNEY DISEASE WHO UNDERWENT COVID-19.
11. Nazarova, N. O. K., Jabbarov, A. A., Madazimova, D. H., Mirzayeva, G. P., & Buvamuhamedova, N. T. (2021). Decreased gene $\text{tgf-}\beta 1$ are associated with renal damage in female patients with lyupus nephritis. *Oriental renaissance: Innovative, educational, natural and social sciences*, 1(11), 1200-1203.
12. Jumaev, N. A., Baratov, N. Y., & Utegenov Yu, M. (2025). DIAGNOSIS OF PARAESOPHAGEAL HERNIAS: A COMPREHENSIVE REVIEW. *AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE*, 3(5), 342-354.
13. Dadajonov, E. M., Safargaliev, F. R., Kholdorov, A. A., Baratov, N. Y., & Sh, I. B. (2016). SPECIFICS OF THE COURSE OF ACUTE CALCULOUS CHOLECYSTITIS IN PATIENTS WITH DIABETES MELLITUS. *Университетская наука: взгляд в будущее*, 246.
14. Утегенов, Ю. М., & филиал Ташкентского, Н. ИСПОЛЬЗОВАНИЕ СОВРЕМЕННЫХ МЕТОДОВ ПЕДАГОГИЧЕ-СКИХ ТЕХНОЛОГИЙ В ПРЕПОДАВАНИИ НОРМАЛЬНОЙ ФИЗИОЛОГИИ В ВЫСШИХ МЕДИЦИНСКИХ УЧЕБНЫХ ЗАВЕДЕНИЯХ.
15. Утегенов, Ю. М., & Жолдасбаев, А. А. (2018). К ВОПРОСУ ИЗУЧЕНИЯ ФИЗИОЛОГИЧЕСКИХ ОСОБЕННОСТЕЙ ОРГАНОВ ВНЕШНЕГО ДЫХАНИЯ У ДЕТЕЙ. *Экономика и социум*, (6 (49)), 1215-1218.
16. Алланиязов, Б. Н., Пахратдинова, Г. А., Алиярова, Г. С., & Утегенов, Ю. М. (2019). ОСОБЕННОСТИ ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ СИСТЕМЫ КРОВИ У ДЕТЕЙ, ПРОЖИВАЮЩИХ В КАРАКАЛПАКСТАНЕ. *Экономика и социум*, (1-1 (56)), 174-177.



17. Сайидбурхонов, С. С., Хайитов, И. Б., Уринбоев, Ж. Э., Уткиров, М. М., & Рузиев, Ш. А. (2024). АНАЛИЗ ЭФФЕКТИВНОСТИ ГАСТРОШУНТИРОВАНИЯ ВЛЕЧЕНИИ МОРБИДНОГО ОЖИРЕНИЯ. *Eurasian Journal of Medical and Natural Sciences*, 5(1), 105-109.
18. Baxodirovich, X. I., & Aralovich, R. Z. S. (1999). POST-BARIATRIC FUNCTIONAL CHANGES IN GI TRACT: PHARMACOLOGICAL EFFECTS AND IMMUNE RESPONSES. *ИНФЕКЦИЯ, ИММУНИТЕТ И ФАРМАКОЛОГИЯ*, 253.
19. Jumaev, N., Teshaev, O., Lim, I., & Kurbanov, G. (2025). Calibration Bougie Size Selection in Sleeve Gastrectomy: A Systematic Review and Meta-Analysis. *Obesity Surgery*, 1-7.
20. Jumaev, N. A., Teshaev, O. R., Kurbanov, G. I., Juraev, J. Z., Lim, I. I., & Lekomseva, M. J. (2025). POSTOPERATIVE MANAGEMENT OF PATIENTS AFTER BARIATRIC SURGERY. *Central Asian Journal of Medicine*, (5), 83-87.
21. Jumaev, N. A., Teshaev, O. R., Juraev, J. Z., Lim, I. I., Gulomova, M. J., & Kurbanov, G. I. (2025). Revisional Bariatric Surgery: Indications, Techniques and Outcomes-A Comprehensive Review. *International Journal of Medical Sciences And Clinical Research*, 5(05), 105-110.
22. Teshaev, O. R., Kurbanov, G. I., & Jumaev, N. A. (2025). MICROSURGICAL RECONSTRUCTION OF POST-BURN SCAR CONTRACTURES: CONTEMPORARY APPROACHES AND OUTCOMES. *Eurasian Journal of Medical and Natural Sciences*, 5(5-2), 36-44.
23. Jumaev, N. A., Urinboyev, J. E., & Kurbanov, G. I. (2025). ABDOMINOPLASTY AFTER BARIATRIC SURGERY: A COMPREHENSIVE APPROACH TO POST-WEIGHT LOSS BODY CONTOURING. *Eurasian Journal of Medical and Natural Sciences*, 5(5-2), 26-35.
24. Баратов, Н., Утегенов, Ю., Курбанов, Г., Ўткиров, М., Ўринбоев, Ж., & Тошназарова, Н. (2025, October). СОВРЕМЕННЫЕ ТЕНДЕНЦИИ ЛЕЧЕНИЯ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ЯЗВЕННОЙ БОЛЕЗНЬЮ ЖЕЛУДКА И



ДВЕНАДЦАТИПЕРСТНОЙ КИШКИ. In International Conference on Medicine & Agriculture (Vol. 1, No. 1, pp. 25-29).

25. Усмонов, М. М., Баратов, Н. Я., & Бобошарипов, Ф. Г. (2017). Лечение больных с синдромом диабетической стопы. *Биология и интегративная медицина*, (2), 42-54.

26. Рахимова, Г. П. (2022). Особенности почечной гемодинамике при кардиоренального синдрома (Doctoral dissertation, Ташкент).

27. Жаббаров, О. О., Джуманиязова, З. Ф., & Рахимова, Г. П. (2022). Клинико-патогенетические аспекты кардиоренального синдрома.

28. Назарова, Н., Мирзаева, Г., Хасанова, М., & Рахимова, Г. (2024). ОСОБЕННОСТИ КЛИНИКИ И ДИАГНОСТИКИ ИШЕМИЧЕСКОЙ НЕФРОПАТИИ. *Академические исследования в современной науке*, 3(44), 119-121.

29. Mirzaeva, G., Nazarova, N., Rakhimova, G., & Xasanova, M. (2024). TREATMENT OF HIGH BLOOD PRESSURE IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE. *Современные подходы и новые исследования в современной науке*, 3(15), 116-118

30. Rakhimova, G. (2024). DEVELOPMENT OF CARDIORENAL SYNDROME IN PATIENTS WITH ARTERIAL HYPERTENSION. *Академические исследования в современной науке*, 3(44), 112-113.

31. Тягунов, А. Е., Ермаков, И. В., Тавадов, А. В., Куценко, И. И., Курбанов, Г. И., & Сажин, А. В. (2022). Множественные перфорации кишечника на фоне терапии бевацизумабом. Обзор литературы и клинический случай. *Московский хирургический журнал*, (3), 66-73.

32. ТЯГУНОВ, А., ЕРМАКОВ, И., ТАВАДОВ, А., КУЦЕНКО, И., КУРБАНОВ, Г., & САЖИН, А. МОСКОВСКИЙ ХИРУРГИЧЕСКИЙ ЖУРНАЛ. *МОСКОВСКИЙ ХИРУРГИЧЕСКИЙ ЖУРНАЛ Учредители: ООО "Профиль-2С"*, (3), 66-73.



33. Бобошарипов, Ф. Г., Холов, Х. А., Тешаев, О. Р., & Надирова, Ю. И. (2023). ПОСТБАРИАТРИЧЕСКАЯ ГИПОГЛИКЕМИЯ И ГИПОТОНИЯ. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, 21(5), 105-113.
34. Надирова, Ю. И., Жаббаров, О. О., Бобошарипов, Ф. Г., Турсунова, Л. Д., & Мирзаева, Г. П. (2023). ОЦЕНКА ЭФФЕКТИВНОСТИ И ОПТИМИЗАЦИЯ ДЕЗАГГРЕГАНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ИБС.